Cytek Biosciences (CTKB) Interest & Investment Income (2020 - 2026)

Cytek Biosciences (CTKB) has reported Interest & Investment Income for 7 consecutive years, with $819000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income rose 47.57% year-over-year to $819000.0; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (down 19.07% YoY), and the FY2025 full-year result was $2.2 million, down 56.73% from the prior year.
• Interest & Investment Income rose to $819000.0 in Q2 2026 per CTKB's latest filing, from $787000.0 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $2.6 million in Q4 2022 and bottomed at $18000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $1.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 14488.89% in 2022, then sank 62.62% in 2025.
• Over 5 years, Interest & Investment Income stood at $2.6 million in 2022, then tumbled by 44.86% to $1.4 million in 2023, then plunged by 36.95% to $913000.0 in 2024, then sank by 36.47% to $580000.0 in 2025, then soared by 41.21% to $819000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $819000.0, $787000.0, and $580000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.